With an estimated 1 million patients affected in the US, thyroid eye disease is a burden for some disorders which become sight-threatening in upto 5% of the cases. Until today, only one thyroid eye disease treatment drug for adults has been approved by the FDA.
Developed by Horizon Therapeutics (now acquired by Amgen), TEPEZZA (teprotumumab), an insulin-like growth factor-1 receptor inhibitor (IGF-1R), is a fully human IgG1 monoclonal antibody produced in Chinese hamster ovary (CHO-DG44) cells with a molecular weight of approximately 148 KD.
TEPEZZA is approved for thyroid eye disease treatment in the US, Brazil, and Saudi Arabia. It is given to pati...
